ST. LOUIS, Oct. 27, 2015 /PRNewswire/
-- Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading
Life Science and Technology Company, announced today it has signed
an agreement with UC San Francisco's (UCSF) Catalyst Program to
support its research efforts. Under the agreement, a Sigma-Aldrich
representative will participate in reviewing and consulting for
projects in the Catalyst Awards program, which funds UCSF
scientists who wish to move their translational research into
product development.
The goal of the alliance is to foster the exchange of scientific
and business ideas between UCSF and Sigma-Aldrich research and
business leaders, delivering transformative value
for Sigma-Aldrich, its partners and customers. As part
of the involvement in the UCSF Catalyst Awards review panel,
Sigma-Aldrich is expected to provide technical insight and market
guidance to enable rapid translation into useful research tools and
reagents. This will offer UCSF the support to focus on research and
development in pursuit of innovative new technologies and
sustainable solutions.
"We are excited to enter into this strategic collaboration with
a world-leading research organization such as UC San Francisco,"
said Sean Muthian, Ph.D., Director
of Strategic Marketing at Sigma-Aldrich. "We hope that
Sigma-Aldrich's partnership with the UCSF Catalyst Program will
make advanced technologies readily available to translational
researchers and speed the development of therapies to improve the
quality of life. In addition, our commitment to standardizing the
manufacture, delivery and use of these tools may help address some
of the challenges of reproducibility with home-brewed research
materials."
"This collaboration marks an important step in cultivating
critical industry-academic partnerships," said June Lee, M.D., Director of the UCSF Catalyst
Program. "Sigma-Aldrich has deep expertise and industry-leading
capabilities that are complementary to the scientific work at UCSF,
and we look forward to partnering with Sigma-Aldrich to further
support the broader mandate of the organization and the Catalyst
Awards, to accelerate research that will ultimately lead to
improved human health."
The Catalyst Awards program solicits applications from UCSF
investigators with compelling translational research findings who
wish to move beyond the research bench and into product
development. It includes four different tracks of focus, including
therapeutics, diagnostics, devices and digital health. Applications
are reviewed by a panel of expert advisors who have specialized
experience related to product development and
commercialization.
The alliance with the UCSF Catalyst Program is part of
Sigma-Aldrich's continued commitment to provide scientists with the
tools and support that will enable and enhance life science
discovery. Sigma-Aldrich has also
established agreements with The Scripps
Research Institute and VIB to accelerate the
commercialization of novel translational tools. These partnerships
are at the core of Sigma-Aldrich's mission to supply researchers
with the products, resources and support they need for their
translational research while addressing industry-wide
reproducibility concerns.
For more information on Sigma-Aldrich's translational research
initiative, visit www.sigma-aldrich.com/translational.
Cautionary Statement: The foregoing release contains
forward-looking statements that can be identified by terminology
such as "will allow," "will provide," "is expected," "hoped," or
similar expressions, or by expressed or implied discussions
regarding potential future revenues from products derived there
from. You should not place undue reliance on these statements. Such
forward-looking statements reflect the current views of management
regarding future events, and involve known and unknown risks,
uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or
achievements expressed or implied by such statements. There can be
no guarantee that this or any other joint venture will assist the
Company to achieve any particular levels of revenue in the future.
In particular, management's expectations regarding this joint
venture could be affected by, among other things, the Company's
ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general;
government, industry and general public pricing pressures; the
impact that the foregoing factors could have on the values
attributed to the Company's assets and liabilities as recorded in
its consolidated balance sheet, and other risks and factors
referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated, believed, estimated or expected.
Sigma-Aldrich is providing the
information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
About Sigma-Aldrich: Sigma-Aldrich, a leading
Life Science and Technology company focused on enhancing human
health and safety, manufactures and distributes 250,000 chemicals,
biochemicals and other essential products to more than 1.4 million
customers globally in research and applied labs as well as in
industrial and commercial markets. With three distinct business
units - Research, Applied and SAFC Commercial - Sigma-Aldrich is
committed to enabling science to improve the quality of life. The
Company operates in 37 countries, has approximately 9,700 employees
worldwide and had sales of $2.79
billion in 2014. For more information about Sigma-Aldrich,
please visit its website at www.sigma-aldrich.com.
Sigma-Aldrich is a trademark of
Sigma-Aldrich Co, LLC registered in the US and other countries.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sigma-aldrich-announces-strategic-collaboration-with-uc-san-franciscos-catalyst-program-to-accelerate-commercialization-of-innovative-research-tools-300166260.html
SOURCE Sigma-Aldrich Corporation